HC Wainwright Reaffirms “Buy” Rating for Agenus (NASDAQ:AGEN)

HC Wainwright reaffirmed their buy rating on shares of Agenus (NASDAQ:AGEN) in a report published on Friday morning, Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock.

AGEN has been the topic of a number of other research reports. B. Riley decreased their price target on shares of Agenus from $120.00 to $100.00 and set a buy rating on the stock in a research note on Monday, March 18th. StockNews.com started coverage on shares of Agenus in a research note on Wednesday, April 17th. They issued a hold rating on the stock.

Agenus Trading Up 10.3 %

AGEN opened at $13.62 on Friday. The stock has a market capitalization of $286.02 million, a P/E ratio of -1.06 and a beta of 1.25. Agenus has a 12 month low of $4.78 and a 12 month high of $42.60. The firm’s fifty day simple moving average is $10.26 and its 200 day simple moving average is $12.79.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) EPS for the quarter, topping the consensus estimate of ($3.58) by $0.54. The business had revenue of $28.01 million for the quarter, compared to the consensus estimate of $40.70 million. On average, equities research analysts predict that Agenus will post -9.7 EPS for the current fiscal year.

Hedge Funds Weigh In On Agenus

Hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock worth $208,000 after purchasing an additional 123,058 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after purchasing an additional 4,134,232 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in Agenus by 81.3% during the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 84,477 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Agenus by 2.5% during the first quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 13,604 shares during the last quarter. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.